Procter & Gamble Health Limited has informed the Exchange about Investor Presentation
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Health shared its investor presentation following a virtual analyst meet on June 16, 2025, covering FY 2024-25 results. The fiscal year was a 9-month transitional period (July 2024 to March 2025) as the company shifted its year-end to April-March. Sales grew 8% while profit after tax surged 27% versus the comparable 9-month period last year. Productivity initiatives delivered INR 40 crore in savings. Over the past 5 years, the company posted a 7% sales CAGR and 9% PAT CAGR with a 34% rise in ROE. Key brands like Neurobion and Evion are driving growth, supported by e-commerce expansion and rural distribution.
The sharp PAT growth (27%) outpacing sales growth (8%) signals meaningful margin expansion, likely to be viewed positively by investors. Strong long-term shareholder value creation and category tailwinds in India's VMS segment reinforce a stable outlook.